袁静梅

学历、职称：博士/博士后、副教授、硕士生导师

研究方向：（1）有机小分子药物的设计、合成及其抗肿瘤活性研究；

（2）以G-四链体及其解旋酶为靶点的药物化学与化学生物学研究。

Email：yuanjm9@nnnu.edu.cn

教育与研究经历

2022.06~至今：南宁师范大学，化学与材料学院，专任教师（副教授）；

2020.05~2022.05：中山大学，药学院，博士后；

2016.09~2019.12：广西师范大学，化学与药学学院，理学博士学位；

2013.09~2016.06：广西师范大学，化学与药学学院，理学硕士学位。

教学情况

主讲《无机及分析化学》、《无机化学实验》和《化学学科前沿》等多门本科生课程。

主持承担科研项目

（1）南宁师范大学博士科研启动基金项目：在研，主持。

（2）广西自然科学基金青年科学基金项目：新型喹唑啉类MDM2-p53/HDAC双靶点抑制剂的设计、合成及抗肿瘤作用研究，在研，主持。

（3）广东省基础与应用基础研究基金自然科学基金项目面上项目：c-myc G-四链体和HDAC双靶点新型小分子抑制剂的设计、合成和抗癌作用机制研究，2021A1515010059，2021.01~2023.12，在研，主持。

（4）中国博士后科学基金第68批面上项目：c-myc G-四链体和HDAC双靶点抗肿瘤先导化合物的发现及作用机制研究，2020M683143，2021.01~2022.6，主持，结题。

（5）中山大学高校基本科研业务费青年教师培育项目：Isaindigotone类G-四链体和HDAC双靶点抑制剂的设计合成及抗肿瘤机制研究，2021.01~2023.12，主持，结题。

（6）中山大学高校基本科研业务费青年教师团队项目：协同作用于G-四链体与组蛋白去乙酰化酶抑制剂的设计合成及抗肿瘤研究，2022.01~2022.12，主持，结题。

（7）广西研究生教育创新计划博士研究生创新厅级项目：3-(2-苯并噻唑基)-4(1H)喹啉酮的合成、结构优化及其诱导肿瘤细胞Caspase非依赖性死亡研究，YCBZ2018032，主持，结题。

主要学术成果（^#共同第一作者，*通讯作者）

[1] Mao-Lin Li^#, Jing-Mei Yuan^#, Hao Yuan, Bi-Han Wu, Shi-Liang Huang, Qing-Jiang Li, Tian-Miao Ou, Hong-Gen Wang, Jia-Heng Tan, Shuo-Bin Chen* and Zhi-Shu Huang*. Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective c-MYC Transcription Repressors Targeting the Promoter G-Quadruplex. J. Med. Chem. 2022, 65, 12675. (中科院一区，IF = 8.039)

[2] Guo-Hai Zhang^#, Jing-Mei Yuan^# (与导师并列一作), Gang Qian, Chen-Xi Gu, Kai Wei, Dong-Liang Mo, Jiang-Ke Qin, Yan Peng, Zu-Ping Zhou, Cheng-Xue Pan^*, Gui-Fa Su^*. Phthalazino[1,2‑b]quinazolinones as p53 activators: cell cycle arrest, apoptotic response and Bak−Bcl-xl complex reorganization in bladder cancer cells. J. Med. Chem. 2017, 60, 6853. (中科院一区，IF = 8.039)

[3] Jing-Mei Yuan^#, Kai Wei^#, Guo-Hai Zhang, Nan-Ying Chen, Xin-Wei Wei, Cheng-Xue Pan^*, Dong-Liang Mo^*, Gui-Fa Su^*. Cryptolepine-Aromathecins-based mimics as potent DNA-cleavage and anticancer agents: design, synthesis and DNA targeting-induced apoptosis. Eur. J. Med. Chem. 2019, 169, 144. (中科院一区，IF = 7.088)

[4] Xin-Wei Wei^#, Jing-Mei Yuan^#, Guo-Hai Zhang, Cheng-Xue Pan^*, Dong-Liang Mo^*, Gui-Fa Su^*. 2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation and in vivo effective anticancer agents. Eur. J. Med. Chem. 2020, 186, 111851. (中科院一区，IF = 7.088)

[5] Jing-Mei Yuan^#, Jinnan Li^#, Heyang Zhou^#, Jiali Xu, Fengting Zhu, Qiuli Liang, Zhiping Liu, Guobao Huang^*, Jun Huang^*. Synthesis of 3-sulfonylquinolines by visible-light promoted metal-free cascade cycloaddition involving N-propargylanilines and sodium sulfinates. New J. Chem. 2020, 44, 3189.

[6] Jing-Mei Yuan^#, Nan-Ying Chen^#, Hao-Ran Liao, Guo-Hai Zhang, Xiao-Juan Li, Zi-Yu Gu, Cheng-Xue Pan^*, Dong-Liang Mo^*, Gui-Fa Su^*. 3-(Benzo[d]thiazol-2-yl)-4-aminoquinolin -e derivatives as novel scaffold topoisomerase I inhibitor via DNA intercalation: design, synthesis, and antitumor activities. New J. Chem. 2020, 44, 11203.

[7] Guo-Xue He^#, Jing-Mei Yuan^# (Co-first author), Hai-Miao Zhu, Kai Wei, Ling-Yun Wang, Shi-Lin Kong, Dong-Liang Mo, Cheng-Xue Pan^*, Gui-Fa Su^*. Synthesis and antitumor evaluation of 2,3-diarylbenzofuran derivatives on HeLa cells. Bioorg. Med. Chem. Lett. 2017, 27, 1660.

[8] Congyu Li^#, Jing-Mei Yuan^# (Co-first author), Wenqiang Chen, Yimiao He, Jun Huang, Yanmin Huang, Qi Xiao, Jiarong Sheng, and Chusheng Huang. Defluorinative C(sp³)-P Bond Construction for the Synthesis of Phosphorylation gem-Difluoroalkenes under Catalyst- and Oxidant-Free Conditions. Chemistry-An Asian journal 2019, 14, 2584.

[9] Nan-Ying Chen^#, Ke Lu^#, Jing-Mei Yuan, Xiao-Juan Li, Zi-Yu Gu, Cheng-Xue Pan^*, Dong-Liang Mo^*, Gui-Fa Su^*. 3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/Mtor signaling pathways to activate P53 and induce apoptosis. Bioorg. Chem. 2021, 114, 105101.

[10] Haitao Cui^#, Caijin Ban^#, Fengting Zhu, Jingmei Yuan, Juan Du, Yanmin Huang, Qi Xiao, Chusheng Huang, Jun Huang*, Qiang Zhu*. Difluorocarbene-Triggered Acyl Rearrangement Reaction: A Strategy for the Direct Introduction of the gem Difluoromethylene Group. Org. Lett. 2023, 25, 99.

[11] Guo-Hai Zhang, Wen-Bin Xue, Yun-Feng An, Jing-Mei Yuan, Jiang-Ke Qin, Cheng-Xue Pan^*, Gui-Fa Su^*. Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function. Eur. J. Med. Chem. 2015, 95, 377.

[12] Qing-Qing Liu^#, Ke Lu^#, Hai-Miao Zhu, Shi-Lin Kong, Jing-Mei Yuan, Guo-Hai Zhang, Nan-Ying Chen, Chen-Xi Gu, Cheng-Xue Pan^*, Dong-Liang Mo^*, Gui-Fa Su^*. Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo. Eur. J. Med. Chem. 2019, 165, 293.